RESULT AND DISCUSSION
ASCVD, fasting TG ≥1.7 mmol/L, CHD, TG, T2DM, dyslipidemia
EVENTS, ASCVD, PANCREATITIS, DYSLIPIDEMIA
To our knowledge, this is the first randomized controlled trial to compare the TG lowering effect of xuezhikang and a synthetic statin, pravastatin, in the fasting and postprandial states of patients with T2DM and dyslipidemia without ASCVD. Xuezhikang is a lipid-lowering agent that has been proven to reduce cholesterol levels and incidence of cardiovascular events, as well as overall mortality in Chinese patients with CHD in several studies [TG control may be interrupted by fasting glucose levels [In this study, a high TG level is defined as fasting TG ≥1.7 mmol/L and <5.6 mmol/L. It has been reported that fasting TG levels ≥5.6 mmol/L are associated with a high risk of pancreatitis, and other TG-lowering agents such as fibrates, niacin, and omega-3 fatty acids are needed [In addition, a 2019 expert panel statement pointed out that ASCVD risk is more closely related to postprandial TG levels than fasting TG levels [Lp(a), similar in structure to LDL, is an atherogenic lipoprotein, and a high Lp(a) level is related to an increased residual ASCVD risk [